LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab

Yasodha Natkunam; Pedro Farinha; Eric D Hsi; Christine P Hans; Robert Tibshirani; Laurie H Sehn; Joseph M Connors; Dita Gratzinger; Manuel Rosado; Shuchun Zhao; Brad Pohlman; Nicholas Wongchaowart; Martin Bast; Abraham Avigdor; Ginette Schiby; Arnon Nagler; Gerald E Byrne; Ronald Levy; Randy D Gascoyne; Izidore S Lossos

doi:10.1200/JCO.2007.13.0690

Back

LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab

Journal article

Peer reviewed

LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab

Yasodha Natkunam, Pedro Farinha, Eric D Hsi, Christine P Hans, Robert Tibshirani, Laurie H Sehn, Joseph M Connors, Dita Gratzinger, Manuel Rosado, Shuchun Zhao, …

Journal of clinical oncology, Vol.26(3), pp.447-454

2008-01-20

DOI: https://doi.org/10.1200/JCO.2007.13.0690

PMID: 18086797

Abstract

Purpose The heterogeneity of diffuse large B-cell lymphoma (DLBCL) has prompted the search for new markers that can accurately separate prognostic risk groups. We previously showed in a multivariate model that LMO2 mRNA was a strong predictor of superior outcome in DLBCL patients. Here, we tested the prognostic impact of LMO2 protein expression in DLBCL patients treated with anthracycline-based chemotherapy with or without rituximab. Patients and Methods DLBCL patients treated with anthracycline-based chemotherapy alone (263 patients) or with the addition of rituximab (80 patients) were studied using immunohistochemistry for LMO2 on tissue microarrays of original biopsies. Staining results were correlated with outcome. Results In anthracycline-treated patients, LMO2 protein expression was significantly correlated with improved overall survival (OS) and progression-free survival (PFS) in univariate analyses (OS, P = .018; PFS, P = .010) and was a significant predictor independent of the clinical International Prognostic Index (IPI) in multivariate analysis. Similarly, in patients treated with the combination of anthracycline-containing regimens and rituximab, LMO2 protein expression was also significantly correlated with improved OS and PFS (OS, P = .005; PFS, P = .009) and was a significant predictor independent of the IPI in multivariate analysis. Conclusion We conclude that LMO2 protein expression is a prognostic marker in DLBCL patients treated with anthracycline-based regimens alone or in combination with rituximab. After further validation, immunohistologic analysis of LMO2 protein expression may become a practical assay for newly diagnosed DLBCL patients to optimize their clinical management.

Metrics

8 Record Views

133 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.130 Lymphomas; 1.130.132 Lymphoma
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab
Creators: Yasodha Natkunam - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Pedro Farinha - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Eric D Hsi - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Christine P Hans - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Robert Tibshirani - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Laurie H Sehn - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Joseph M Connors - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Dita Gratzinger - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Manuel Rosado - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Shuchun Zhao - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Brad Pohlman - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Nicholas Wongchaowart - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Martin Bast - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Abraham Avigdor - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Ginette Schiby - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Arnon Nagler - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Gerald E Byrne - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Ronald Levy - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Randy D Gascoyne - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Izidore S Lossos - From the Department of Pathology and Department of Medicine, Division of Oncology, Stanford University School of Medicine; Departments of Health Research and Policy and Statistics, Stanford University, Stanford, CA; Departments of Clinical Pathology and Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH; Departments of Pathology and Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Medicine, Division of Hematology-Oncology and Molecular and
Publication Details: Journal of clinical oncology, Vol.26(3), pp.447-454
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
PMID: 18086797
Record Identifier: 991031560043602976